每年出版 12 期
ISSN 打印: 1521-9437
ISSN 在线: 1940-4344
Indexed in
Blood Lymphocyte and Neutrophil Response of Cultured Rainbow Trout, Oncorhynchus mykiss, Administered Varying Dosages of an Oral Medicinal Mushroom-Based Immunomodulator"Fin-ImmuneTM"
摘要
In a 10-week (May−August 2008) Phase I trial, 840 1+-year-old rainbow trout, Oncorhynchus mykiss, received a commercial oral immunomodulator, Fin-ImmuneTM, at four different dosages (0, 10, 20, and 30 mg/g−1) to evaluate immune response and growth. The overall objective was to determine an optimal dosage of this product for rainbow trout that provides enhanced immunity with maximal growth and health. Biweekly blood samples were taken from 10 randomly selected fish in each tank (30 samples per treatment) to evaluate the duration of enhanced immunity conferred by Fin-ImmuneTM. The immunological assessment included serum white blood cell (lymphocyte and neutrophil) densities and blood hematocrit (packed cell volume %). Of these three variables, only lymphocyte density increased significantly among trout fed Fin-ImmuneTM at 20 and 30 mg/g−1, which peaked at week 6. At week 7, all trout were switched to regular feed (lacking Fin-ImmuneTM), and by week 10, lymphocyte levels decreased among all levels but were still greater than at week 0. There was growth impairment at the highest dose of Fin-ImmuneTM tested (30 mg/g−1), which can be associated with a physiological compensatory mechanism due to a dose-specific threshold level. Thus, our main objective of this Phase I study was achieved: the 20 mg/g−1 dose of Fin-ImmuneTM should be the most efficacious (of those we tested) to use for a Phase II disease-challenge trial.